Pretreatment plasma immunoglobulin A and survival outcomes with pembrolizumab plus necitumumab in programmed death-ligand 1-high advanced non-small cell lung cancer: an exploratory substudy of the phase II K-TAIL-202 trial (ESMO-IO 2026) - Oct 25, 2026 - Abstract #8P; Pres time: Dec 14, 2026; 05:30 PM - 06:30 PM; Location: Churchill Room; No abstract available
Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1
|
|
Ryotaro Ohkuma; Aya Misawa; Hiroshi Wakui; Shunichi Sugawara; Yuji Minegishi; Sa datomo Tasaka; Toshio Sakatani; Hiroy uki Suzuki; Yukio Hosomi; Yuichi Tam bo; Eisaku Miyauchi; Katsuhiko Naoki; Tatsuro Fukuhara; Sachiko Takeno shita; Kiyoshi Yoshimura; Hironori Sagar a; Shinichi Kobayashi; Takuya Tsunoda; Satoshi Wada; Atsushi Horiike
|